TY - JOUR
T1 - Racial Differences in Cutaneous Events Among Patients Receiving Enfortumab Vedotin
AU - Vlachou, Evangelia
AU - Mamtani, Ronac
AU - Hahn, Noah M.
AU - III, Burles Johnson
AU - Hoffman-Censits, Jean
AU - Nimgaonkar, Vivek
N1 - Publisher Copyright:
© 2024 Elsevier Inc.
PY - 2024/6
Y1 - 2024/6
N2 - Introduction: Enfortumab vedotin (EV) is an antibody–drug conjugate approved alone and in combination with pembrolizumab for advanced urothelial cancer (UC). EV-related-cutaneous-events (EVCEs) are common and rarely life-threatening. Black patients are frequently under-represented in oncology trials, and dermatologic conditions may vary with race. Methods: Therefore, this retrospective analysis investigated differences in EVCE frequency between Black and White patients in an urban cohort (Johns Hopkins [JH]) and a US-based, nationwide electronic health record (EHR)-derived deidentified database (Flatiron Health [FH]) with sub-group analysis of those who had received prior pembrolizumab. Results: The study included 12 Black patients in the JH Cohort (17.1%) and 24 Black patients in the FH Cohort (7.6%). In both cohorts, the frequency of EVCEs among Black patients was higher compared to White patients (JH: 66.7% vs. 33.3%; FH: 25.0% vs. 15.8%), though not statistically significant. In the larger FH Cohort EVCEs were significantly more common among Black compared to White patients treated with prior pembrolizumab (Odds Ratio [OR]: 4.76 [95%CI: 1.42, 15.95]) and recent pembrolizumab (within 90 days of EV initiation) (OR 9.00 [95%CI: 1.94, 41.66]). Conclusion: This hypothesis-generating retrospective study, comprising the largest population of EV-treated Black patients reported to date, emphasizes the importance of attentiveness to EVCEs among Black patients, particularly with receipt of pembrolizumab.
AB - Introduction: Enfortumab vedotin (EV) is an antibody–drug conjugate approved alone and in combination with pembrolizumab for advanced urothelial cancer (UC). EV-related-cutaneous-events (EVCEs) are common and rarely life-threatening. Black patients are frequently under-represented in oncology trials, and dermatologic conditions may vary with race. Methods: Therefore, this retrospective analysis investigated differences in EVCE frequency between Black and White patients in an urban cohort (Johns Hopkins [JH]) and a US-based, nationwide electronic health record (EHR)-derived deidentified database (Flatiron Health [FH]) with sub-group analysis of those who had received prior pembrolizumab. Results: The study included 12 Black patients in the JH Cohort (17.1%) and 24 Black patients in the FH Cohort (7.6%). In both cohorts, the frequency of EVCEs among Black patients was higher compared to White patients (JH: 66.7% vs. 33.3%; FH: 25.0% vs. 15.8%), though not statistically significant. In the larger FH Cohort EVCEs were significantly more common among Black compared to White patients treated with prior pembrolizumab (Odds Ratio [OR]: 4.76 [95%CI: 1.42, 15.95]) and recent pembrolizumab (within 90 days of EV initiation) (OR 9.00 [95%CI: 1.94, 41.66]). Conclusion: This hypothesis-generating retrospective study, comprising the largest population of EV-treated Black patients reported to date, emphasizes the importance of attentiveness to EVCEs among Black patients, particularly with receipt of pembrolizumab.
KW - Advanced urothelial cancer
KW - Antibody drug conjugate
KW - Black patients
KW - Bladder cancer
KW - Cutaneous adverse events
UR - http://www.scopus.com/inward/record.url?scp=85191881875&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85191881875&partnerID=8YFLogxK
U2 - 10.1016/j.clgc.2024.102090
DO - 10.1016/j.clgc.2024.102090
M3 - Article
C2 - 38688798
AN - SCOPUS:85191881875
SN - 1558-7673
VL - 22
JO - Clinical Genitourinary Cancer
JF - Clinical Genitourinary Cancer
IS - 3
M1 - 102090
ER -